A tissue-engineered stent for cell-based vascular gene transfer

Carmelo J. Panetta, Katsumi Miyauchi, David Berry, Robert D. Simari, David Holmes, Robert S. Schwartz, Noel M. Caplice

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Cell-based gene transfer using a stent platform would provide a significant advantage in terms of site-specific gene expression in the vasculature. The current study presents a novel stent design that allows stable in vivo transgene expression over a 4-week period in the vasculature. A mesh-stent coated with fibronectin provided an excellent platform for adherent porcine smooth muscle cells (SMC). Autologous porcine SMC were stably transduced with a plasmid encoding green fluorescence protein (GFP), seeded at high density in the mesh-stent, and deployed in the porcine coronary artery. Stable in vivo GFP expression within the mesh-stent (5.2 × 10 5 GFP-positive cells/cm 2 mesh) was demonstrated 1 month after implantation in the porcine coronary artery by fluorescence microscopy and flow cytometry. No significant change in GFP positive cell number within the stent occurred over a 1-month period in vivo when compared to preinsertion. Angiographic and histologic analysis revealed mild neointimal proliferation and no inflammatory infiltrate in the stented segment. This study has implications for treatment of cardiovascular and other diseases where long-term cell-based delivery of transgene is a desirable therapeutic option.

Original languageEnglish (US)
Pages (from-to)433-441
Number of pages9
JournalHuman Gene Therapy
Volume13
Issue number3
DOIs
StatePublished - 2002

Fingerprint

Stents
Blood Vessels
Swine
Fluorescence
Genes
Transgenes
Smooth Muscle Myocytes
Coronary Vessels
Proteins
Fluorescence Microscopy
Fibronectins
Flow Cytometry
Plasmids
Cardiovascular Diseases
Cell Count
Gene Expression

ASJC Scopus subject areas

  • Genetics

Cite this

Panetta, C. J., Miyauchi, K., Berry, D., Simari, R. D., Holmes, D., Schwartz, R. S., & Caplice, N. M. (2002). A tissue-engineered stent for cell-based vascular gene transfer. Human Gene Therapy, 13(3), 433-441. https://doi.org/10.1089/10430340252792567

A tissue-engineered stent for cell-based vascular gene transfer. / Panetta, Carmelo J.; Miyauchi, Katsumi; Berry, David; Simari, Robert D.; Holmes, David; Schwartz, Robert S.; Caplice, Noel M.

In: Human Gene Therapy, Vol. 13, No. 3, 2002, p. 433-441.

Research output: Contribution to journalArticle

Panetta, CJ, Miyauchi, K, Berry, D, Simari, RD, Holmes, D, Schwartz, RS & Caplice, NM 2002, 'A tissue-engineered stent for cell-based vascular gene transfer', Human Gene Therapy, vol. 13, no. 3, pp. 433-441. https://doi.org/10.1089/10430340252792567
Panetta, Carmelo J. ; Miyauchi, Katsumi ; Berry, David ; Simari, Robert D. ; Holmes, David ; Schwartz, Robert S. ; Caplice, Noel M. / A tissue-engineered stent for cell-based vascular gene transfer. In: Human Gene Therapy. 2002 ; Vol. 13, No. 3. pp. 433-441.
@article{96fa85b8d5a645008a721007c1603218,
title = "A tissue-engineered stent for cell-based vascular gene transfer",
abstract = "Cell-based gene transfer using a stent platform would provide a significant advantage in terms of site-specific gene expression in the vasculature. The current study presents a novel stent design that allows stable in vivo transgene expression over a 4-week period in the vasculature. A mesh-stent coated with fibronectin provided an excellent platform for adherent porcine smooth muscle cells (SMC). Autologous porcine SMC were stably transduced with a plasmid encoding green fluorescence protein (GFP), seeded at high density in the mesh-stent, and deployed in the porcine coronary artery. Stable in vivo GFP expression within the mesh-stent (5.2 × 10 5 GFP-positive cells/cm 2 mesh) was demonstrated 1 month after implantation in the porcine coronary artery by fluorescence microscopy and flow cytometry. No significant change in GFP positive cell number within the stent occurred over a 1-month period in vivo when compared to preinsertion. Angiographic and histologic analysis revealed mild neointimal proliferation and no inflammatory infiltrate in the stented segment. This study has implications for treatment of cardiovascular and other diseases where long-term cell-based delivery of transgene is a desirable therapeutic option.",
author = "Panetta, {Carmelo J.} and Katsumi Miyauchi and David Berry and Simari, {Robert D.} and David Holmes and Schwartz, {Robert S.} and Caplice, {Noel M.}",
year = "2002",
doi = "10.1089/10430340252792567",
language = "English (US)",
volume = "13",
pages = "433--441",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "3",

}

TY - JOUR

T1 - A tissue-engineered stent for cell-based vascular gene transfer

AU - Panetta, Carmelo J.

AU - Miyauchi, Katsumi

AU - Berry, David

AU - Simari, Robert D.

AU - Holmes, David

AU - Schwartz, Robert S.

AU - Caplice, Noel M.

PY - 2002

Y1 - 2002

N2 - Cell-based gene transfer using a stent platform would provide a significant advantage in terms of site-specific gene expression in the vasculature. The current study presents a novel stent design that allows stable in vivo transgene expression over a 4-week period in the vasculature. A mesh-stent coated with fibronectin provided an excellent platform for adherent porcine smooth muscle cells (SMC). Autologous porcine SMC were stably transduced with a plasmid encoding green fluorescence protein (GFP), seeded at high density in the mesh-stent, and deployed in the porcine coronary artery. Stable in vivo GFP expression within the mesh-stent (5.2 × 10 5 GFP-positive cells/cm 2 mesh) was demonstrated 1 month after implantation in the porcine coronary artery by fluorescence microscopy and flow cytometry. No significant change in GFP positive cell number within the stent occurred over a 1-month period in vivo when compared to preinsertion. Angiographic and histologic analysis revealed mild neointimal proliferation and no inflammatory infiltrate in the stented segment. This study has implications for treatment of cardiovascular and other diseases where long-term cell-based delivery of transgene is a desirable therapeutic option.

AB - Cell-based gene transfer using a stent platform would provide a significant advantage in terms of site-specific gene expression in the vasculature. The current study presents a novel stent design that allows stable in vivo transgene expression over a 4-week period in the vasculature. A mesh-stent coated with fibronectin provided an excellent platform for adherent porcine smooth muscle cells (SMC). Autologous porcine SMC were stably transduced with a plasmid encoding green fluorescence protein (GFP), seeded at high density in the mesh-stent, and deployed in the porcine coronary artery. Stable in vivo GFP expression within the mesh-stent (5.2 × 10 5 GFP-positive cells/cm 2 mesh) was demonstrated 1 month after implantation in the porcine coronary artery by fluorescence microscopy and flow cytometry. No significant change in GFP positive cell number within the stent occurred over a 1-month period in vivo when compared to preinsertion. Angiographic and histologic analysis revealed mild neointimal proliferation and no inflammatory infiltrate in the stented segment. This study has implications for treatment of cardiovascular and other diseases where long-term cell-based delivery of transgene is a desirable therapeutic option.

UR - http://www.scopus.com/inward/record.url?scp=0036211385&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036211385&partnerID=8YFLogxK

U2 - 10.1089/10430340252792567

DO - 10.1089/10430340252792567

M3 - Article

C2 - 11860710

AN - SCOPUS:0036211385

VL - 13

SP - 433

EP - 441

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 3

ER -